Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
21 Novembro 2023 - 9:00AM
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology
company developing induced pluripotent stem cell (iPSC)-derived
cell therapies in immuno-oncology, today announced that members of
the management team will participate in a fireside chat at the
Piper Sandler 35th Annual Healthcare Conference on Tuesday,
November 28, 2023 at 10:00 AM ET.
A replay of the event will be available on the
“Events & Presentations” page in the “Investors” section of the
Company’s website
at https://investors.centurytx.com/events-and-presentations and
will be available for 90 days following the events.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of
adult stem cells to develop curative cell therapy products for
cancer and autoimmune and inflammatory diseases that we believe
will allow us to overcome the limitations of first-generation cell
therapies. Our genetically engineered, iPSC-derived cell product
candidates are designed to specifically target hematologic and
solid tumor cancers, with a broadening application to autoimmune
and inflammatory diseases. We are leveraging our expertise in
cellular reprogramming, genetic engineering, and manufacturing to
develop therapies with the potential to overcome many of the
challenges inherent to cell therapy and provide a significant
advantage over existing cell therapy technologies. We believe our
commitment to developing off-the-shelf cell therapies will expand
patient access and provide an unparalleled opportunity to advance
the course of cancer and autoimmune and inflammatory disease care.
For more information on Century Therapeutics please visit
www.centurytx.com.
Century Therapeutics Forward-Looking
Statement
This press release contains forward-looking statements within
the meaning of, and made pursuant to the safe harbor provisions of,
The Private Securities Litigation Reform Act of 1995. All
statements contained in this press release, other than statements
of historical facts or statements that relate to present facts or
current conditions, including but not limited to, statements
regarding our clinical development plans and timelines, are
forward-looking statements. These statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance, or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” “might,” “will,” “should,”
“expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “forecast,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this press release are only predictions. We have
based these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control, including, among others: our ability to
successfully advance our current and future product candidates
through development activities, preclinical studies, and clinical
trials; our dependence on the success of our lead product
candidate, CNTY-101; uncertainties inherent in the results of
preliminary data, pre-clinical studies and earlier-stage clinical
trials being predictive of the results of early or later-stage
clinical trials; our ability to obtain FDA acceptance for our
future IND submissions and commence clinical trials on expected
timelines, or at all; our reliance on the maintenance of certain
key collaborative relationships for the manufacturing and
development of our product candidates; the timing, scope and
likelihood of regulatory filings and approvals, including final
regulatory approval of our product candidates; the impact of the
COVID-19 pandemic, geopolitical issues, banking instability and
inflation on our business and operations, supply chain and labor
force; the performance of third parties in connection with the
development of our product candidates, including third parties
conducting our clinical trials as well as third-party suppliers and
manufacturers; our ability to successfully commercialize our
product candidates and develop sales and marketing capabilities, if
our product candidates are approved; our ability to recruit and
maintain key members of management and our ability to maintain and
successfully enforce adequate intellectual property protection.
These and other risks and uncertainties are described more fully in
the “Risk Factors” section of our most recent filings with the
Securities and Exchange Commission and available at www.sec.gov.
You should not rely on these forward-looking statements as
predictions of future events. The events and circumstances
reflected in our forward-looking statements may not be achieved or
occur, and actual results could differ materially from those
projected in the forward-looking statements. Moreover, we operate
in a dynamic industry and economy. New risk factors and
uncertainties may emerge from time to time, and it is not possible
for management to predict all risk factors and uncertainties that
we may face. Except as required by applicable law, we do not plan
to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
For More Information: Investors/Media: Melissa
Forst/Maghan Meyers – century@argotpartners.com
Century Therapeutics (NASDAQ:IPSC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Century Therapeutics (NASDAQ:IPSC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025